Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
25.80
+0.76 (3.04%)
At close: Jun 12, 2026, 4:00 PM EDT
26.30
+0.50 (1.94%)
Pre-market: Jun 15, 2026, 6:09 AM EDT
Capricor Therapeutics Employees
Capricor Therapeutics had 231 employees as of December 31, 2025. The number of employees increased by 71 or 44.38% compared to the previous year.
Employees
231
Change (1Y)
71
Growth (1Y)
44.38%
Revenue / Employee
n/a
Profits / Employee
-$496,077
Market Cap
1.49B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 231 | 71 | 44.38% | 231 | 0 |
| Dec 31, 2024 | 160 | 58 | 56.86% | 160 | 0 |
| Dec 31, 2023 | 102 | 28 | 37.84% | 101 | 1 |
| Dec 31, 2022 | 74 | 26 | 54.17% | 74 | 0 |
| Dec 31, 2021 | 48 | 22 | 84.62% | 48 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Novavax | 749 |
| Immunocore Holdings | 524 |
| Vir Biotechnology | 367 |
| UroGen Pharma | 298 |
| Monte Rosa Therapeutics | 187 |
| Bicara Therapeutics | 103 |
| AtaiBeckley | 99 |
CAPR News
- 2 days ago - Caprock Announces Proposed Private Placement - Newsfile Corp
- 2 days ago - Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m - Newsfile Corp
- 4 days ago - Capricor Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Capricor Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 16 days ago - Capricor Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital - TheFly
- 4 weeks ago - Capricor Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Capricor Therapeutics Earnings release: Q1 2026 - Filings